We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Sues the FDA over Marketing Exclusivity for Sensipar in Pediatric Patients
Amgen Sues the FDA over Marketing Exclusivity for Sensipar in Pediatric Patients
Amgen is suing the FDA, requesting that its Sensipar medication be granted six additional months of pediatric market exclusivity after it completed three of four pediatric clinical trials requested by the agency.